Lucentis (ranibizumab) 10 mg/mL solution for injection, 1 vial (Novartis) Treatment of macular degeneration. Delivery of medications from Europe, compliance with storage conditions, payment upon receipt, order by phone +380996042415, Viber, WhatsApp.
Delivery methods
- EMC post
Delivery time
- 7-10 days
Payment methods
- Payment to Revolut card
Display
- Treatment of neovascular (exudative) age-related macular degeneration (AMD).
- Treatment of impaired vision in diabetic macular plaque (DMS).
- Remedial treatment of impaired vision with macular plaque, which is the result of venous thrombosis network (thrombosis of the central vein of the network or thrombosis of the central vein of the network).
- Treatment of impaired vision due to choroidal neovascularization (CNV), secondary pathological myopia (PM).
-
The recommended dose of Lucentis is 0.5 mg for a single intravitreal injection. This dose corresponds to an injection volume of 0.05 ml. The interval between the administration of two doses in one eye is due to become less than 4 years.
Start the treatment with one injection per month and continue until the maximum visual acuity is reached or signs of disease activity are observed, then change the visual acuity Other symptoms of illness. Patients with exudative AMD, DMN, and renal vein thrombosis may require three or more postoperative injections.
- Trade Name:LUCENTIS
- Chemical Name:Ranibizumab
- Dosage:10 mg
- Quantity:1
- Form of Issue:Flacon
No reviews yet
